Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Azetukalner's Promise | Xenon's lead drug candidate shows potential in epilepsy and major depressive disorder, with blockbuster sales projections and upcoming clinical milestones |
Pipeline Progress | Explore Xenon's robust clinical development program, including Phase 3 trials for focal onset seizures and plans for MDD studies |
Market Opportunity | Delve into the substantial market potential for azetukalner, with analysts projecting over $1 billion in sales within 3-5 years post-launch |
Financial Health | Learn about Xenon's strong liquidity position and analyst optimism, with price targets ranging from $55 to $65, despite current unprofitability |
Metrics to compare | XENE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipXENEPeersSector | |
---|---|---|---|---|
P/E Ratio | −10.2x | −4.5x | −0.5x | |
PEG Ratio | 0.53 | 0.02 | 0.00 | |
Price/Book | 3.6x | 1.8x | 2.6x | |
Price / LTM Sales | 342.0x | 8.9x | 3.3x | |
Upside (Analyst Target) | 64.5% | 318.4% | 43.4% | |
Fair Value Upside | Unlock | 6.9% | 7.1% | Unlock |